Kalata B1 [T16S]

General Information


DRACP ID  DRACP02588

Peptide Name   Kalata B1 [T16S]

Sequence  GLPVCGETCVGGTCNSPGCTCSWPVCTRN

Sequence Length  29

UniProt ID  P56254 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane lysis



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma CC50=43.8±0.5 μM Resazurin assay 2, 24 h 1

Hemolytic Activity  Human erythrocytes: Weak active up to 50 µM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02588

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C116H185N35O40S6

Absent amino acids  ADFHIKMQY

Common amino acids  C

Mass  340193

Pl  5.94

Basic residues  1

Acidic residues  1

Hydrophobic residues  5

Net charge  0

Boman Index  -2034

Hydrophobicity  14.83

Aliphatic Index  43.45

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  5875

Absorbance 280nm  209.82

Polar residues  19

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 25099014

Title  Anticancer and toxic properties of cyclotides are dependent on phosphatidylethanolamine phospholipid targeting

Doi 10.1002/cbic.201402144

Year  2014

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_12208

DRACP is developed by Dr.Zheng's team.